Thygeson's superficial punctate keratitis (TSPK) is a rare, bilateral, chronic epithelial keratopathy characterized by recurrent exacerbations and remissions. Although its pathophysiology remains unclear, immunological and viral mechanisms have been implicated, with associations reported between TSPK and HLA-DR3. Similarly, celiac disease (CD) is an autoimmune disorder linked to HLA-DQ2 and HLA-DQ8, and HLA-DR3-DQ2. We report the case of a 20-year-old female with celiac disease who presented with TSPK. Clinical findings included stellate epithelial opacities and a pseudo-dendritic lesion, treated successfully with artificial tears, topical cyclosporine A, and therapeutic contact lenses. This case highlights a rare association between TSPK and CD, potentially explained by shared HLA genotypes, underscoring the need for further investigation into their immunogenetic link.

The aim of this study was to elucidate a rare corneal association of the coronavirus disease 2019 (COVID-19) vaccine. Although cases of corneal involvement after vaccination have been reported, we present the first case of Thygeson superficial punctate keratitis (TSPK) linked to the COVID-19 vaccine. This study is a case report. A 25-year-old woman was assessed in the ophthalmology clinic for recurrent ocular surface symptoms after receiving the COVID-19 vaccine. She was followed in clinic and was found to have a remitting and recurring pattern of bilateral intraepithelial corneal opacities with associated subepithelial haze primarily overlying the pupillary area. These corneal lesions responded well to topical corticosteroid ophthalmic drops. Based on the clinical appearance, the response to treatment, negative herpes simplex virus serology, and the temporal relationship between vaccination and ocular findings, a diagnosis of COVID-19 vaccine-induced TSPK was suspected. Although the COVID-19 vaccine remains overwhelmingly safe, clinicians should be aware of possible corneal side effects, including TSPK. Prompt ophthalmic assessment in those presenting with ocular symptoms after vaccination is encouraged.

Thygeson superficial punctate keratitis (TSPK) is clinically characterized by exacerbations and remissions of gray-white opacities within the corneal epithelium, most often bilateral but may be asymmetric. Symptoms typically include photophobia, tearing, blurring, and eye irritation. Although disease progression and prognosis are well described, the exact cause is unknown. Hypotheses exist implicating virus-mediated immunity as the cause of TSPK following cases of viral keratitis; however, several polymerase chain reaction studies refute the infectious process concurrently with symptomatic TSPK. This is further supported by the consistent lack of response to antiviral and antibacterial treatment. A subset of dendritic cells known as Langerhans cells (LC) found within the corneal epithelium has been positively correlated with exacerbations of TSPK. Langerhans cells proliferate to protect and mitigate the cornea's inflammatory response, but the inflammatory triggers and relapses associated with TSPK are not well understood. Several topical drugs exist to treat inflammation related to TSPK; however, drug delivery is a major barrier to treatment because of the tear film and epithelial barrier. Drug-eluting contact lenses that target intermediates of inflammation could serve as a more effective treatment modality because of the increased bioavailability of the drugs. This review is an in-depth survey of the literature regarding the relationship between the origin and pathophysiology of LC and TSPK at the immunologic level. We also discuss potential pharmacotherapeutic interventions for TSPK prevention and treatment.

The corneal epithelium serves as a physical barrier and a refractive element. Therefore, diseases of the corneal epithelium can increase the risk for infection and causes vision loss. The corneal epithelium can be affected by a multitude of conditions, such as infections, hereditary diseases, depositions, trauma, autoimmune conditions, factitious disorders, and iatrogenic causes. Non-infectious and non-hereditary corneal epithelial diseases represent a collection of conditions with diverse etiologies and clinical presentations but similar patient symptoms. The differing therapeutic interventions for each condition make clinical distinction important. The clinical characteristics, disease course, pathophysiology and current treatments for non-infectious, non-hereditary corneal epithelial diseases are reviewed.

To describe bilateral microsporidial keratoconjunctivitis in healthy individuals with long-term follow-up. Six cases of smear-positive bilateral microsporidial keratoconjunctivitis were diagnosed and followed up during the study period August 2017 to January 2019. Associated risk factors, clinical features, coexistence with adenovirus, clinical course, and recurrence were studied. The mean age was 36.6 years (range: 10-65 years). The mean duration of symptoms was 13.6 days (range: 7-60 days). Predisposing risk factors were present in 4 of 6 cases. The best-corrected visual acuity at presentation was ≥20/30 in all eyes except in one. Typical microsporidial epithelial lesions were seen in only one case. Persistent lesions, clinically resembling Thygeson superficial punctate keratitis in both eyes, were observed in 3 cases. The lesions in 5 eyes resolved with topical lubricants, and the remaining 7 eyes were treated with topical steroids and tacrolimus 0.03%. Complete resolution was seen in 5 eyes at the end of 1 month, and superficial scarring at the last follow-up was seen in 5 eyes. The best-corrected visual acuity was ≤20/30 in 3 eyes at the last follow-up. The mean duration of follow-up was 7.3 months (range: 3-12 mo). Bilateral microsporidial keratoconjunctivitis in healthy patients has an atypical presentation with prolonged course. Microsporidia could be implicated as potential candidates in the etiopathogenesis of Thygeson superficial punctate keratitis.